This work is licensed under the Creative Commons Attribution 4.0 International License.
Auer K, Bachmayr-Heyda A, Sukhbaatar N, Aust S, Schmetterer KG, Meier SM, et al. Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer. Oncotarget 2016; 7: 61336–54. doi: 10.18632/oncotarget.11038AuerKBachmayr-HeydaASukhbaatarNAustSSchmettererKGMeierSMRole of the immune system in the peritoneal tumor spread of high grade serous ovarian cancerOncotarget20167613365410.18632/oncotarget.11038Open DOISearch in Google Scholar
Wefers C, Duiveman-de Boer T, Yigit R, Zusterzeel PLM, van Altena AM, Massuger LFAG, et al. Survival of ovarian cancer patients is independent of the presence of DC and T cell subsets in ascites. Front Immunol 2019; 11: 3156–65. doi: 10.3389/fimmu.2018.03156WefersCDuiveman-de BoerTYigitRZusterzeelPLMvan AltenaAMMassugerLFAGSurvival of ovarian cancer patients is independent of the presence of DC and T cell subsets in ascitesFront Immunol20191131566510.3389/fimmu.2018.03156Open DOISearch in Google Scholar
du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd international gynecologic cancer intergroup ovarian cancer consensus conference (GCIG OCCC 2004). Ann Oncol 2005; 16(Suppl 8): viii7–12. doi: 10.1093/annonc/mdi961du BoisAQuinnMThigpenTVermorkenJAvall-LundqvistEBookmanM2004 consensus statements on the management of ovarian cancer: final document of the 3rd international gynecologic cancer intergroup ovarian cancer consensus conference (GCIG OCCC 2004)Ann Oncol200516Suppl 8viii71210.1093/annonc/mdi961Open DOISearch in Google Scholar
Zhu C, Xu Z, Zhang T, Qian L, Xiao W, Wei H, et al. Updates of pathogenesis, diagnostic and therapeutic perspectives for ovarian clear cell carcinoma. J Cancer 2021; 12: 2295–316. doi: 10.7150/jca.53395ZhuCXuZZhangTQianLXiaoWWeiHUpdates of pathogenesis, diagnostic and therapeutic perspectives for ovarian clear cell carcinomaJ Cancer202112229531610.7150/jca.53395Open DOISearch in Google Scholar
Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203–13. doi: 10.1056/NEJMoa020177ZhangLConejo-GarciaJRKatsarosDGimottyPAMassobrioMRegnaniGIntratumoral T cells, recurrence, and survival in epithelial ovarian cancerN Engl J Med20033482031310.1056/NEJMoa020177Open DOISearch in Google Scholar
Webb JR, Milne K, Watson P, Deleeuw RJ, Nelson BH. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res 2014; 20: 434–44. doi: 10.1158/1078-0432.CCR-13-1877WebbJRMilneKWatsonPDeleeuwRJNelsonBHTumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancerClin Cancer Res2014204344410.1158/1078-0432.CCR-13-1877Open DOISearch in Google Scholar
Gupta P, Chen C, Chaluvally-Raghavan P, Pradeep SB. Cells as an immune-regulatory signature in ovarian cancer. Cancers 2019; 11: 894–903. doi: 10.3390/cancers11070894GuptaPChenCChaluvally-RaghavanPPradeepSBCells as an immune-regulatory signature in ovarian cancerCancers20191189490310.3390/cancers11070894Open DOISearch in Google Scholar
Gupta V, Yull F, Khabele D. Bipolar tumor-associated macrophages in ovarian cancer as targets for therapy. Cancers 2018; 10: 366–98. doi: 10.3390/cancers10100366GuptaVYullFKhabeleDBipolar tumor-associated macrophages in ovarian cancer as targets for therapyCancers2018103669810.3390/cancers10100366Open DOISearch in Google Scholar
Piętak P, Pietrzyk N, Pawłowska A, Suszczyk D, Bednarek W, Kotarski J, et al. The meaning of PD-1/PD-L1 pathway in ovarian cancer pathogenesis. Wiad Lek 2018; 71: 1089–94.PiętakPPietrzykNPawłowskaASuszczykDBednarekWKotarskiJThe meaning of PD-1/PD-L1 pathway in ovarian cancer pathogenesisWiad Lek201871108994Search in Google Scholar
Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, et al. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3− T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One 2013; 8: e80063. doi: 10.1371/journal.pone.0080063PrestonCCMaurerMJObergALVisscherDWKalliKRHartmannLCThe ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3− T cells correlate with poor clinical outcome in human serous ovarian cancerPLoS One20138e8006310.1371/journal.pone.0080063Open DOISearch in Google Scholar
Nakano M, Ito M, Tanaka R, Yamaguchi K, Ariyama H, Mitsugi K, et al. PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer. Cancer Sci 2018; 109: 2986–92. doi: 10.1111/cas.13723NakanoMItoMTanakaRYamaguchiKAriyamaHMitsugiKPD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancerCancer Sci201810929869210.1111/cas.13723Open DOISearch in Google Scholar
Miceska S, Škof E, Novaković S, Stegel V, Jeričević A, Grčar Kuzmanov B, et al. Cytopathological assessment is an accurate method for identifying immunophenotypic features and BRCA1/2 mutations of high-grade serous carcinoma from ascites. Cancer Cytopathol 2023; 131: 188–97. doi: 10.1002/cncy.22664MiceskaSŠkofENovakovićSStegelVJeričevićAGrčar KuzmanovBCytopathological assessment is an accurate method for identifying immunophenotypic features and BRCA1/2 mutations of high-grade serous carcinoma from ascitesCancer Cytopathol20231311889710.1002/cncy.22664Open DOISearch in Google Scholar
Brozic A, Pohar Marinsek Z, Novakovic S, Kloboves Prevodnik V. Inconclusive flow cytometric surface light chain results can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas? Diagn Pathol 2015; 20: 191–201. doi: 10.1186/s13000-015-0427-5BrozicAPohar MarinsekZNovakovicSKloboves PrevodnikVInconclusive flow cytometric surface light chain results can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas?Diagn Pathol20152019120110.1186/s13000-015-0427-5Open DOISearch in Google Scholar
Hoogstad-van Evert JS, Bekkers R, Ottevanger N, Jansen JH, Massuger L, Dolstra H. Harnessing natural killer cells for the treatment of ovarian cancer. Gynecol Oncol 2020; 157: 810–6. doi: 10.1016/j.ygyno.2020.03.020Hoogstad-van EvertJSBekkersROttevangerNJansenJHMassugerLDolstraHHarnessing natural killer cells for the treatment of ovarian cancerGynecol Oncol2020157810610.1016/j.ygyno.2020.03.020Open DOISearch in Google Scholar
Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer 2020; 123: 9–16. doi: 10.1038/s41416-020-0875-xFordCEWernerBHackerNFWartonKThe untapped potential of ascites in ovarian cancer research and treatmentBr J Cancer202012391610.1038/s41416-020-0875-xOpen DOISearch in Google Scholar
Sato S, Matsushita H, Shintani D, Kobayashi Y, Fujieda N, Yabuno A, et al. Association between effector-type regulatory T cells and immune checkpoint expression on CD8+ T cells in malignant ascites from epithelial ovarian cancer. BMC Cancer 2022; 22: 437–45. doi: 10.1186/s12885-022-09534-zSatoSMatsushitaHShintaniDKobayashiYFujiedaNYabunoAAssociation between effector-type regulatory T cells and immune checkpoint expression on CD8+ T cells in malignant ascites from epithelial ovarian cancerBMC Cancer2022224374510.1186/s12885-022-09534-zOpen DOISearch in Google Scholar
Steitz AM, Steffes A, Finkernagel F, Unger A, Sommerfeld L, Jansen JM, et al. Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C. Cell Death Dis 2020; 11: 249–63. doi: 10.1038/s41419-020-2438-8SteitzAMSteffesAFinkernagelFUngerASommerfeldLJansenJMTumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin CCell Death Dis2020112496310.1038/s41419-020-2438-8Open DOISearch in Google Scholar
Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004; 64: 5535–8. doi: 10.1158/0008-5472.CAN-04-1272CurielTJChengPMottramPAlvarezXMoonsLEvdemon-HoganMDendritic cell subsets differentially regulate angiogenesis in human ovarian cancerCancer Res2004645535810.1158/0008-5472.CAN-04-1272Open DOISearch in Google Scholar
Almeida-Nunes DL, Mendes-Frias A, Silvestre R, Dinis-Oliveira RJ, Ricardo S. Immune tumor microenvironment in ovarian cancer ascites. Int J Mol Sci 2022; 23: 10692–714. doi: 10.3390/ijms231810692Almeida-NunesDLMendes-FriasASilvestreRDinis-OliveiraRJRicardoSImmune tumor microenvironment in ovarian cancer ascitesInt J Mol Sci2022231069271410.3390/ijms231810692Open DOISearch in Google Scholar
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 18538–43. doi: 10.1073/pnas.0509182102SatoEOlsonSHAhnJBundyBNishikawaHQianFIntraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancerProc Natl Acad Sci U S A2005102185384310.1073/pnas.0509182102Open DOISearch in Google Scholar
Ning F, Cole CB, Annunziata CM. Driving immune responses in the ovarian tumor microenvironment. Front Oncol 2021; 10: 604084. doi: 10.3389/fonc.2020.604084NingFColeCBAnnunziataCMDriving immune responses in the ovarian tumor microenvironmentFront Oncol20211060408410.3389/fonc.2020.604084Open DOISearch in Google Scholar
Singh M, Loftus T, Webb E, Benencia F. Minireview: regulatory T cells and ovarian cancer. Immunol Invest 2016; 45: 712–20. doi: 10.1080/08820139.2016.1186689SinghMLoftusTWebbEBenenciaFMinireview: regulatory T cells and ovarian cancerImmunol Invest2016457122010.1080/08820139.2016.1186689Open DOISearch in Google Scholar
Knutson KL, Maurer MJ, Preston CC, Moysich KB, Goergen K, Hawthorne KM, et al. Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. Cancer Immunol Immunother 2015; 64: 1495–504. doi: 10.1007/s00262-015-1753-xKnutsonKLMaurerMJPrestonCCMoysichKBGoergenKHawthorneKMRegulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancerCancer Immunol Immunother201564149550410.1007/s00262-015-1753-xOpen DOISearch in Google Scholar
Hoffmann JC, Schön MP. Integrin αE(CD103)β7 in epithelial cancer. Cancers 2021; 13: 6211–29. doi: 10.3390/cancers13246211HoffmannJCSchönMPIntegrin αE(CD103)β7 in epithelial cancerCancers20211362112910.3390/cancers13246211Open DOISearch in Google Scholar
Laumont CM, Wouters MCA, Smazynski J, Gierc NS, Chavez EA, Chong LC, et al. Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes coexpressing CD39, CD103, and PD-1 in ovarian cancer. Clin Cancer Res 2021; 27: 4089–100. doi: 10.1158/1078-0432.CCR-20-4394LaumontCMWoutersMCASmazynskiJGiercNSChavezEAChongLCSingle-cell profiles and prognostic impact of tumor-infiltrating lymphocytes coexpressing CD39, CD103, and PD-1 in ovarian cancerClin Cancer Res202127408910010.1158/1078-0432.CCR-20-4394Open DOISearch in Google Scholar
Webb JR, Wick DA, Nielsen JS, Tran E, Milne K, McMurtrie E, et al. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer. Gynecol Oncol 2010; 118: 228–36. doi: 10.1016/j.ygyno.2010.05.016WebbJRWickDANielsenJSTranEMilneKMcMurtrieEProfound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancerGynecol Oncol20101182283610.1016/j.ygyno.2010.05.016Open DOISearch in Google Scholar
Bösmüller HC, Wagner P, Peper JK, Schuster H, Pham DL, Greif K, et al. Combined immunoscore of CD103 and CD3 identifies long-term survivors in high-grade serous ovarian cancer. Int J Gynecol Cancer 2016; 26: 671–9. doi: 10.1097/IGC.0000000000000672BösmüllerHCWagnerPPeperJKSchusterHPhamDLGreifKCombined immunoscore of CD103 and CD3 identifies long-term survivors in high-grade serous ovarian cancerInt J Gynecol Cancer201626671910.1097/IGC.0000000000000672Open DOISearch in Google Scholar
Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, et al. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol 2006; 125: 451–8.DongHPElstrandMBHolthASilinsIBernerATropeCGNK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinomaAm J Clin Pathol20061254518Search in Google Scholar
Wei X, Jin Y, Tian Y, Zhang H, Wu J, Lu W, et al. Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients. Tumour Biol 2016; 37: 6581–8. doi: 10.1007/s13277-015-4538-0WeiXJinYTianYZhangHWuJLuWRegulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patientsTumour Biol2016376581810.1007/s13277-015-4538-0Open DOISearch in Google Scholar
Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 2012; 18: 3281–92. doi: 10.1158/1078-0432.CCR-12-0234NielsenJSSahotaRAMilneKKostSENesslingerNJWatsonPHCD20+ tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancerClin Cancer Res20121832819210.1158/1078-0432.CCR-12-0234Open DOISearch in Google Scholar
Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, et al. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J Immunother Cancer 2018; 6: 139–51. doi: 10.1186/s40425-018-0446-3TruxovaIKasikovaLHenslerMSkapaPLacoJPecenLMature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patientsJ Immunother Cancer201861395110.1186/s40425-018-0446-3Open DOISearch in Google Scholar
Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011; 71: 5423–34. doi: 10.1158/0008-5472.CAN-11-0367Labidi-GalySISisirakVMeeusPGobertMTreilleuxIBajardAQuantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancerCancer Res20117154233410.1158/0008-5472.CAN-11-0367Open DOISearch in Google Scholar
Ning F, Cole CB, Annunziata CM. Driving immune responses in the ovarian tumor microenvironment. Front Oncol 2021; 10: 604084–98. doi: 10.3389/fonc.2020.604084NingFColeCBAnnunziataCMDriving immune responses in the ovarian tumor microenvironmentFront Oncol2021106040849810.3389/fonc.2020.604084Open DOISearch in Google Scholar
Nersesian S, Glazebrook H, Toulany J, Grantham SR, Boudreau JE. Naturally killing the silent killer: NK cell-based immunotherapy for ovarian cancer. Front Immunol 2019; 10: 1782–97. doi: 10.3389/fimmu.2019.01782NersesianSGlazebrookHToulanyJGranthamSRBoudreauJENaturally killing the silent killer: NK cell-based immunotherapy for ovarian cancerFront Immunol20191017829710.3389/fimmu.2019.01782Open DOISearch in Google Scholar
Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013; 121: 3599–608. doi: 10.1182/blood-2012-04-425397RomeeRFoleyBLenvikTWangYZhangBAnkarloDNK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)Blood2013121359960810.1182/blood-2012-04-425397Open DOISearch in Google Scholar
Larionova I, Tuguzbaeva G, Ponomaryova A, Stakheyeva M, Cherdyntseva N, Pavlov V, et al. Tumor-associated macrophages in human breast, colorectal, lung, ovarian and prostate cancers. Front Oncol 2020; 10: 566511–44. doi: 10.3389/fonc.2020.566511LarionovaITuguzbaevaGPonomaryovaAStakheyevaMCherdyntsevaNPavlovVTumor-associated macrophages in human breast, colorectal, lung, ovarian and prostate cancersFront Oncol2020105665114410.3389/fonc.2020.566511Open DOISearch in Google Scholar
Hoover AA, Hufnagel DH, Harris W, Bullock K, Glass EB, Liu E, et al. Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer. BMC Cancer 2020; 20: 970–85. doi: 10.1186/s12885-020-07450-8HooverAAHufnagelDHHarrisWBullockKGlassEBLiuEIncreased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancerBMC Cancer2020209708510.1186/s12885-020-07450-8Open DOISearch in Google Scholar
Nowak M, Klink M. The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer. Cells 2020; 9: 1299–300. doi: 10.3390/cells9051299NowakMKlinkMThe role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancerCells20209129930010.3390/cells9051299Open DOISearch in Google Scholar
Osborn G, Stavraka C, Adams R, Sayasneh A, Ghosh S, Montes A, et al. Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies. Clin Exp Immunol 2022; 209: 4–21. doi: 10.1093/cei/uxab020OsbornGStavrakaCAdamsRSayasnehAGhoshSMontesAMacrophages in ovarian cancer and their interactions with monoclonal antibody therapiesClin Exp Immunol202220942110.1093/cei/uxab020Open DOISearch in Google Scholar
Leary A, Tan D, Ledermann J. Immune checkpoint inhibitors in ovarian cancer: where do we stand? Ther Adv Med Oncol 2021; 13: 17588359211039899. doi: 10.1177/17588359211039899LearyATanDLedermannJImmune checkpoint inhibitors in ovarian cancer: where do we stand?Ther Adv Med Oncol2021131758835921103989910.1177/17588359211039899Open DOISearch in Google Scholar
Imai Y, Hasegawa K, Matsushita H, Fujieda N, Sato S, Miyagi E, et al. Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma. Oncol Lett 2018; 15: 6457–68. doi: 10.3892/ol.2018.8101ImaiYHasegawaKMatsushitaHFujiedaNSatoSMiyagiEExpression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinomaOncol Lett20181564576810.3892/ol.2018.8101Open DOISearch in Google Scholar
Pawłowska A, Suszczyk D, Tarkowski R, Paduch R, Kotarski J, Wertel I. et al. Programmed death-1 receptor (PD-1) as a potential prognosis biomarker for ovarian cancer patients. Cancer Manag Res 2020; 12: 9691–709. doi: 10.2147/CMAR.S263010PawłowskaASuszczykDTarkowskiRPaduchRKotarskiJWertelIProgrammed death-1 receptor (PD-1) as a potential prognosis biomarker for ovarian cancer patientsCancer Manag Res202012969170910.2147/CMAR.S263010Open DOISearch in Google Scholar
Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget 2016; 7: 1486–99. doi: 10.18632/oncotarget.6429Darb-EsfahaniSKunzeCAKulbeHSehouliJWienertSLindnerJPrognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinomaOncotarget2016714869910.18632/oncotarget.6429Open DOISearch in Google Scholar
Xu M, Zhang B, Zhang M, Liu Y, Yin FL, Liu X, et al. Clinical relevance of expression of B7-H1 and B7-H4 in ovarian cancer. Oncol Lett 2016; 11: 2815–19. doi: 10.3892/ol.2016.4301XuMZhangBZhangMLiuYYinFLLiuXClinical relevance of expression of B7-H1 and B7-H4 in ovarian cancerOncol Lett20161128151910.3892/ol.2016.4301Open DOISearch in Google Scholar
Cai J, Wang D, Zhang G, Guo X. The role Of PD-1/PD-L1 axis in Treg development and function: Implications for cancer immunotherapy. Onco Targets Ther 2019; 12: 8437–45. doi: 10.2147/OTT.S221340CaiJWangDZhangGGuoXThe role Of PD-1/PD-L1 axis in Treg development and function: Implications for cancer immunotherapyOnco Targets Ther20191284374510.2147/OTT.S221340Open DOISearch in Google Scholar